Anika Gains FDA Clearance for HA-based Bone Void Filler

Anika Therapeutics received FDA 510(k) clearance to market a resorbable, injectable hyaluronic acid-based bone void filler, SCS 17-01.

As we noted in coverage of ANIK's 3Q17 revenue, the company had submitted the application within 3Q17.

Orthopaedic surgeon John Tierney, D.O., who has worked with the product, remarked, "Anika’s 510(k)...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us